Ropivacaine-Poloxamer 407 Gel for Pain Control After Open Gastrectomy

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Gastric Cancer

In brief

The study evaluates the efficacy of Ropivacaine-Poloxamer 407 hydrogel in reducing postoperative pain following open gastrectomy.

Key facts

Study ID

NCT06778954

Run by

Gangnam Severance Hospital

People needed

48

Starts

2025-01-30

Expected to finish

2025-12-31

Last updated by the study team

2025-02-14

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a histologically confirmed diagnosis of gastric adenocarcinoma prior to surgery.
• Patients who have undergone a complete surgical resection (R0 resection).
• Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.
• Patients aged 20 years or older.

You may not qualify if…

• Patients under 19 years of age.
• Presence of ascites or peritoneal metastasis.
• Patients who have undergone preoperative chemotherapy or radiotherapy.
• Diagnosis of malignancies other than gastric cancer.
• Uncontrolled diabetes, autoimmune diseases, hypertrophic scars, or keloid history affecting wound healing.
• History of allergy or adverse reactions to Ropivacaine or other local anesthetics.
• Pregnant women.
• Patients with preoperative chronic pain conditions, including CRPS.
• Patients with long-term preoperative use of opioid analgesics.
• Patients with psychiatric disorders deemed likely to interfere with study participation.
• Patients with severe liver disease, renal disease, or arrhythmia.

Where it is running

• GangnamSeverance Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.